respiratory syncytial virus (RSV)

(iStock image)

New tool helps identify babies at high risk for RSV

A new tool to identify infants most at risk for severe respiratory syncytial virus (RSV) illness could aid pediatricians in prioritizing children under 1 to receive a preventive medication before RSV season (October-April).

Study finds most infants receiving ICU-level care for RSV had no underlying medical condition

A Vanderbilt study found that most infants admitted to the intensive care or high acuity unit for respiratory syncytial virus (RSV) infections during fall 2022 were previously healthy and born at term.

James Crowe, Jr., MD, left, and Naveenchandra Suryadevara, PhD, have discovered a monoclonal antibody with therapeutic potential that neutralizes both RSV and hMPV. (photo by Anthony Czelusniak)

Researchers discover antibody that neutralizes both RSV and hMPV

Vanderbilt and Stanford University researchers discovered a potent, cross-neutralizing human monoclonal antibody against the respiratory syncytial virus and human metapneumovirus.

A clinical trial supports approval of a new medication to treat moderate-to-severe asthma in children.

Study finds early RSV infection linked to significantly increased risk of asthma in children

A Vanderbilt study has found that RSV infection in the first year of life is associated with a significantly increased risk of asthma in children.

Study finds RSV may evade vaccines via rapid mutation

A Vanderbilt study concluded that RSV’s ability to mutate rapidly to escape detection by the body’s immune system makes it more challenging to design and develop vaccines that can stop it from spreading.

A clinical trial supports approval of a new medication to treat moderate-to-severe asthma in children.

Study explores role RSV plays in later asthma development

A Vanderbilt clinical project will follow 1,950 Middle Tennessee children to determine how genes and the environment interact with RSV infection during the first year of life and contribute to asthma development

1 2 3